- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 213
Crux lucks out in $20m series B
Goldman Sachs and Citi have returned to back a $20m series B round for Crux Informatics that almost doubled its overall funding to $41m.
Oct 26, 2018Cethik buys into NextVPU’s series A vision
The China Electronics Technology Group subsidiary has invested $28.7m in NextVPU, which will use the funds for R&D, recruitment and the pursuit of its growth strategy.
Oct 25, 2018Investors pump $20m into Gauss
Gauss Surgical has received series C funding from SoftBank and eight healthcare providers including Northwell Health, OSF Healthcare and Providence Healthcare.
Oct 25, 2018Investors pump $20m into Gauss
Stanford-StartX Fund's portfolio company Gauss Surgical has received series C funding from SoftBank and eight healthcare providers.
Oct 25, 2018Qpex cues up $33m series A
Qpex Biopharma, which was spun off to develop The Medicines Company's anti-infective drug assets, has received $33m in its series A round.
Oct 24, 2018Silk spins $30m from series B
The natural chemistry developer has increased its funding to $50m altogether, in a Kraft Group-backed round that will support an expansion into the textile industry.
Oct 24, 2018Unifonic tunes into $21m series A
The Saudi Telecom-anchored STV led the round, while Raed Ventures also invested in cloud communications technology provider Unifonic.
Oct 23, 2018Aledade adds $23m to latest round
GV-backed care manager Aledade has doubled the size of its latest funding round to $46m and increased its overall funding to $100m.
Oct 23, 2018Unifonic tunes into $21m series A
The Saudi Telecom-anchored STV led the round, while Raed Ventures also invested in cloud communications technology provider Unifonic.
Oct 23, 2018Qpex tackles $33m series A
Qpex has raised $33m in series A funding from Stanford University Draper Fund and others after spinning out of the Medicines Company to develop drugs targeting superbugs.
Oct 23, 2018About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


